Dominik Witzigmann

12.1k total citations · 11 hit papers
64 papers, 9.1k citations indexed

About

Dominik Witzigmann is a scholar working on Molecular Biology, Biomaterials and Pharmaceutical Science. According to data from OpenAlex, Dominik Witzigmann has authored 64 papers receiving a total of 9.1k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Molecular Biology, 14 papers in Biomaterials and 7 papers in Pharmaceutical Science. Recurrent topics in Dominik Witzigmann's work include RNA Interference and Gene Delivery (44 papers), Advanced biosensing and bioanalysis techniques (19 papers) and Lipid Membrane Structure and Behavior (13 papers). Dominik Witzigmann is often cited by papers focused on RNA Interference and Gene Delivery (44 papers), Advanced biosensing and bioanalysis techniques (19 papers) and Lipid Membrane Structure and Behavior (13 papers). Dominik Witzigmann collaborates with scholars based in Canada, Switzerland and Germany. Dominik Witzigmann's co-authors include Jayesh A. Kulkarni, Jörg Huwyler, Pieter R. Cullis, Vimalkumar Balasubramanian, Andreas Wicki, Roy van der Meel, Sam Chen, Philip Grossen, Sandro Sieber and Rein Verbeke and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Advanced Materials.

In The Last Decade

Dominik Witzigmann

64 papers receiving 9.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications

2014 1.5k citations Dominik Witzigmann, Jörg Huwyler et al. Journal of Controlled Release profile →
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs

2019 1.2k citations Akin Akinc, Martin A. Maier et al. Nature Nanotechnology profile →
mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability

2021 1.0k citations Dominik Witzigmann, Jayesh A. Kulkarni et al. profile →
The current landscape of nucleic acid therapeutics

2021 934 citations Jayesh A. Kulkarni, Dominik Witzigmann et al. Nature Nanotechnology profile →
The role of lipid components in lipid nanoparticles for vaccines and gene therapy

2022 718 citations Jayesh A. Kulkarni, Dominik Witzigmann et al. profile →
PEG-PCL-based nanomedicines: A biodegradable drug delivery system and its application

2017 402 citations Philip Grossen, Dominik Witzigmann et al. Journal of Controlled Release profile →
Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics

2019 376 citations Jayesh A. Kulkarni, Dominik Witzigmann et al. profile →
Lipid nanoparticle technology for therapeutic gene regulation in the liver

2020 273 citations Dominik Witzigmann, Jayesh A. Kulkarni et al. profile →
Lipid-Based DNA Therapeutics: Hallmarks of Non-Viral Gene Delivery

2019 266 citations Philip Grossen, Pieter R. Cullis et al. profile →
Anionic Lipid Nanoparticles Preferentially Deliver mRNA to the Hepatic Reticuloendothelial System

2022 144 citations Gabriela Arias‐Alpizar, Genc Basha et al. Advanced Materials profile →
Induction of Bleb Structures in Lipid Nanoparticle Formulations of mRNA Leads to Improved Transfection Potency

2023 129 citations Miffy H. Y. Cheng, Jerry Leung et al. Advanced Materials profile →

Peers

Countries citing papers authored by Dominik Witzigmann

Since Specialization

Citations

This map shows the geographic impact of Dominik Witzigmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dominik Witzigmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dominik Witzigmann more than expected).

Fields of papers citing papers by Dominik Witzigmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dominik Witzigmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dominik Witzigmann. The network helps show where Dominik Witzigmann may publish in the future.

Co-authorship network of co-authors of Dominik Witzigmann

This figure shows the co-authorship network connecting the top 25 collaborators of Dominik Witzigmann. A scholar is included among the top collaborators of Dominik Witzigmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dominik Witzigmann. Dominik Witzigmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Design of cationic ionizable lipids for the delivery of therapeutic nucleic acids 2025 ·Molecular Therapy — Methods & Clinical Development ·(unknown), Fariba Saadati, Jayesh A. Kulkarni, Dominik Witzigmann, Pieter R. Cullis, Marco A. Ciufolini	1
2	Rational design of lipid nanoparticles for enabling gene therapies 2025 ·Molecular Therapy — Methods & Clinical Development ·Cedric A. Brimacombe, Jayesh A. Kulkarni, Miffy H. Y. Cheng, (unknown), Dominik Witzigmann, Pieter R. Cullis	2
3	Liposomal lipid nanoparticles for extrahepatic delivery of mRNA 2025 ·Nature Communications ·Miffy H. Y. Cheng, Yao Zhang, (unknown), Jerry Leung, (unknown), (unknown), Yihang Chen, (unknown), (unknown), Eric Jan, (unknown), Cristina Rodríguez‐Rodríguez, Katayoun Saatchi, Urs O. Häfeli, Amir Abdolahzadeh, Dominik Witzigmann, Pieter R. Cullis	10
4	A Nanocarrier Approach for Oral Peptide Delivery: Evaluation of Cell‐Penetrating‐Peptide‐Modified Liposomal Formulations in Dogs 2023 ·Advanced Therapeutics ·Philipp Uhl, (unknown), Dominik Witzigmann, (unknown), Stefan Zimmermann, Jürgen Burhenne, Johanna Weiß, Walter E. Haefeli, Max Sauter	7
5	Induction of Bleb Structures in Lipid Nanoparticle Formulations of mRNA Leads to Improved Transfection Potency breakdown → 2023 ·Advanced Materials ·Miffy H. Y. Cheng, Jerry Leung, Yao Zhang, (unknown), Genc Basha, Arash Momeni, Yihang Chen, Eric Jan, Amir Abdolahzadeh, Xinying Wang, Jayesh A. Kulkarni, Dominik Witzigmann, Pieter R. Cullis	129
6	Lipid nanoparticle formulations for optimal RNA-based topical delivery to murine airways 2022 ·European Journal of Pharmaceutical Sciences ·Anthony Raymond Tam, Jayesh A. Kulkarni, (unknown), (unknown), Delbert R. Dorscheid, Gurpreet K. Singhera, Pascal Bernatchez, Gregor S. D. Reid, Karen Y. T. Chan, Dominik Witzigmann, P.R. Cullis, DD Sin, Chinten James Lim	27
7	Anionic Lipid Nanoparticles Preferentially Deliver mRNA to the Hepatic Reticuloendothelial System breakdown → 2022 ·Advanced Materials ·(unknown), Gabriela Arias‐Alpizar, Genc Basha, Karen Y. T. Chan, Jeroen Bussmann, Thomas H. Sharp, Mohammad‐Amin Moradi, Nico A. J. M. Sommerdijk, Edward N. Harris, Pieter R. Cullis, Alexander Kros, Dominik Witzigmann, Frederick Campbell	144
8	Lipid nanoparticle-mediated silencing of osteogenic suppressor GNAS leads to osteogenic differentiation of mesenchymal stem cells in vivo 2022 ·Molecular Therapy ·Genc Basha, (unknown), (unknown), Karen Y. T. Chan, Dominik Witzigmann, Robert N. Young, Fábio Rossi, Pieter R. Cullis	16
9	Spray drying siRNA-lipid nanoparticles for dry powder pulmonary delivery 2022 ·Journal of Controlled Release ·(unknown), Domizia Baldassi, Karen Y. T. Chan, Nathan B. P. Adams, (unknown), Diana Porras-Gonzalez, Xin Wei, Nikolaus Kneidinger, Mircea Gabriel Stoleriu, Gerald Burgstaller, Dominik Witzigmann, Paola Luciani, Olivia M. Merkel	96
10	Author Correction: The current landscape of nucleic acid therapeutics 2021 ·Nature Nanotechnology ·Jayesh A. Kulkarni, Dominik Witzigmann, Sarah B. Thomson, Sam Chen, Blair R. Leavitt, Pieter R. Cullis, Roy van der Meel	16
11	The current landscape of nucleic acid therapeutics breakdown → 2021 ·Nature Nanotechnology ·Jayesh A. Kulkarni, Dominik Witzigmann, Sarah B. Thomson, Sam Chen, Blair R. Leavitt, Pieter R. Cullis, Roy van der Meel	934
12	Optimized Photoactivatable Lipid Nanoparticles Enable Red Light Triggered Drug Release 2021 ·Small ·(unknown), Johannes Morstein, (unknown), (unknown), Pieter R. Cullis, Dirk Trauner, Dominik Witzigmann	54
13	Development and characterization of a novel flavopiridol formulation for treatment of acute myeloid leukemia 2021 ·Journal of Controlled Release ·(unknown), (unknown), Malathi Anantha, Dominik Witzigmann, Ada W.Y. Leung, Marcel B. Bally	21
14	In vivo cytidine base editing of hepatocytes without detectable off-target mutations in RNA and DNA 2021 ·Nature Biomedical Engineering ·Lukas Villiger, Tanja Rothgangl, Dominik Witzigmann, Rurika Oka, Paulo J.C. Lin, Weihong Qi, Sharan Janjuha, Christian Berk, Femke Ringnalda, Mitchell Beattie, Markus Stoffel, Beat Thöny, Jonathan Hall, Hubert Rehrauer, Ruben van Boxtel, Ying K. Tam, Gerald Schwank	75
15	Gene Delivery to the Skin – How Far Have We Come? 2020 ·Trends in biotechnology ·Qurrat Ul Ain, Estefânia Vangelie Ramos Campos, (unknown), Dominik Witzigmann, Sarah Hedtrich	31
16	The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs breakdown → 2019 ·Nature Nanotechnology ·Akin Akinc, Martin A. Maier, Muthiah Manoharan, Kevin Fitzgerald, Muthusamy Jayaraman, Scott Barros, Steven M. Ansell, Xinyao Du, Michael J. Hope, Thomas D. Madden, Barbara L. Mui, Sean C. Semple, Ying K. Tam, Marco A. Ciufolini, Dominik Witzigmann, Jayesh A. Kulkarni, Roy van der Meel, Pieter R. Cullis	1160
17	Combined cerium oxide nanocapping and layer-by-layer coating of porous silicon containers for controlled drug release 2018 ·Journal of Materials Science ·Mahsa Sedighi, Fereshteh Rahimi, Ali Hossein Rezayan, Mohammad‐Ali Shahbazi, Dominik Witzigmann, Jörg Huwyler	14
18	Translating nanomedicines: Thinking beyond materials? A young investigator's reply to ‘The Novelty Bubble’ 2018 ·Journal of Controlled Release ·Dominik Witzigmann, Sjoerd Hak, Roy van der Meel	11
19	Zebrafish as an early stage screening tool to study the systemic circulation of nanoparticulate drug delivery systems in vivo 2017 ·Journal of Controlled Release ·Sandro Sieber, Philip Grossen, Pascal Detampel, (unknown), Dominik Witzigmann, Jörg Huwyler	83
20	Loop-miRs: active microRNAs generated from single-stranded loop regions 2013 ·Nucleic Acids Research ·Julia Winter, (unknown), Dominik Witzigmann, (unknown), Christopher Previti, Sven Diederichs	35

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact